About: Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults
Creator	Green, C Sande, C Scarselli, E
Source	Elsevier; Medline; PMC
abstract	Abstract Objectives Respiratory syncytial virus (RSV) causes respiratory infection across the world, with infants and the elderly at particular risk of developing severe disease and death. The replication-defective chimpanzee adenovirus (PanAd3-RSV) and modified vaccinia virus Ankara (MVA-RSV) vaccines were shown to be safe and immunogenic in young healthy adults. Here we report an extension to this first-in-man vaccine trial to include healthy older adults aged 60–75 years. Methods We evaluated the safety and immunogenicity of a single dose of MVA-RSV given by intra-muscular (IM) injection (n = 6), two doses of IM PanAd3-RSV given 4-weeks apart (n = 6), IM PanAd3-RSV prime and IM MVA-RSV boost 8-weeks later (n = 6), intra-nasal (IN) spray of PanAd3-RSV prime and IM MVA-RSV boost 8-weeks later (n = 6), or no vaccine (n = 6). Safety measures included all adverse events within one week of vaccination and blood monitoring. Immunogenicity measures included serum antibody responses (RSV- and PanAd3-neutralising antibody titres measured by plaque-reduction neutralisation and SEAP assays, respectively), peripheral B-cell immune responses (frequencies of F-specific IgG and IgA antibody secreting cells and memory B-cells by ex vivo and cultured dual-colour ELISpot assays respectively), and peripheral RSV-specific T-cell immune responses (frequencies of IFNγ-producing T-cells by ex vivo ELISpot and CD4+/CD8+/Tfh-like cell frequencies by ICS/FACS assay). Results The vaccines were safe and well tolerated. Compared with each individual baseline immunity the mean fold-changes in serum RSV-neutralising antibody, appearance and magnitude of F-specific IgG and IgA ASCs and expansion of CD4+/CD8+ IFNγ-producing T-cells in peripheral circulation were comparable to the results seen from younger healthy adults who received the same vaccine combination and dose. There were little/no IgA memory B-cell responses in younger and older adults. Expansion of IFNγ-producing T-cells was most marked in older adults following IM prime, with balanced CD4+ and CD8+ T cell responses. The RSV-specific immune responses to vaccination did not appear to be attenuated in the presence of PanAd3 (vector) neutralising antibody. Conclusions PanAd3-RSV and MVA-RSV was safe and immunogenic in older adults and the parallel induction of RSV-specific humoral and cellular immunity merits further assessment in providing protection from severe disease.
has issue date	2019-05-31(xsd:dateTime)
bibo:doi	10.1016/j.jinf.2019.02.003
bibo:pmid	30742894
has license	els-covid
sha1sum (hex)	7bb973611fdfdbfb74d3edf94324fa9f723a8965
schema:url	https://doi.org/10.1016/j.jinf.2019.02.003
resource representing a document's title	Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults
has PubMed Central identifier	PMC7172982
has PubMed identifier	30742894
schema:publication	Journal of Infection
resource representing a document's body	covid:7bb973611fdfdbfb74d3edf94324fa9f723a8965#body_text
is schema:about of	named entity 'IFN' named entity 'assays' named entity 'vaccinia virus' named entity 'prime' named entity 'cultured' named entity 'antibody' named entity 'T-cells' named entity 'combination' named entity 'baseline' named entity 'immunogenic' named entity 'cellular immunity' covid:arg/7bb973611fdfdbfb74d3edf94324fa9f723a8965 named entity 'peripheral' named entity 'adenovirus' named entity 'younger' named entity 'parallel' named entity 'vivo' named entity 'assessment' named entity 'vaccine' named entity 'week' named entity 'memory' named entity 'vaccines' named entity 'RSV' named entity 'titres' named entity 'modified' named entity 'weeks' named entity 'comparable' named entity 'B-cell' named entity 'immunity' named entity 'marked' named entity 'RSV' named entity 'immunogenic' named entity 'IgA antibody' named entity 'RSV' named entity 'RSV' named entity 'RSV' named entity 'RSV' named entity 'immune responses' named entity 'vector' named entity 'respiratory infection' named entity 'RSV' named entity 'T-cell' named entity 'adverse events' named entity 'chimpanzee' named entity 'older adults' named entity 'T-cells' named entity 'serum' named entity 'neutralising antibody' named entity 'humoral' named entity 'RSV' named entity 'chimpanzee' named entity 'adenovirus' named entity 'Here' named entity 'vaccine' named entity 'serum' named entity 'neutralising antibody' named entity 'immunopathology' named entity 'neutralising antibody' named entity 'IgA' named entity 'RSV' named entity 'T-cell' named entity 'FACS' named entity 'adeno' named entity 'older adults' named entity 'nucleocapsid' named entity 'vaccine' named entity 'viral replication' named entity 'antibody' named entity 'serum' named entity 'Staphylococcus aureus' named entity 'vaccine' named entity 'IgA' named entity 'infection' named entity 'PBMCs' named entity 'antibody titres' named entity 'RSV' named entity 'adenovirus' named entity 'immunogenicity' named entity 'RSV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software